Loading clinical trials...

COMPLETEDPHASE2

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line

NCT00116467•Cell Genesys

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Initial diagnosis of de novo AML with no preexisting hematologic dysplasia for more than 3 months.
•No prior therapy except leukapheresis or less than 72 hours of hydroxyurea.

Exclusion Criteria

•Prior myelodysplastic disorder, or treatment-related leukemia.
•Prior myeloproliferative disease.
•Acute promyelocytic leukemia (APL).
•Prior chemotherapy for a malignant or nonmalignant disorder.

Locations (4)

University of California, San Francisco

San Francisco, California, United States

University of Chicago

Chicago, Illinois, United States

Johns Hopkins University

Baltimore, Maryland, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Key Dates

Start Date

March 1, 2001

Completion Date

January 1, 2006

Last Updated

December 24, 2007

Enrollment

Estimated participants

Conditions

Acute Myelogenous Leukemia

Interventions

GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)

BIOLOGICAL

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424

AML (Acute Myelogenous Leukemia)Acute Lymphoid Leukemia (ALL)+9 more

View study

RECRUITING

Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combination for Acute Myeloid Leukemia Patients in Remission.

NCT07254312

AML (Acute Myelogenous Leukemia

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 24, 2007Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Inclusion Criteria

Exclusion Criteria

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combination for Acute Myeloid Leukemia Patients in Remission.

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation